Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report third quarter 2026 financial results on Monday, ...
Travere Therapeutics, Inc. (Nasdaq: TVTX) today presented new biomarker data from the Phase 3 PROTECT Study providing ...
Travere Therapeutics reported durable biomarker data for FILSPARI in IgA nephropathy, but shares fell 4.5% as markets focus ...
Travere Therapeutics presented Phase 3 PROTECT biomarker findings suggesting FILSPARI may modify underlying disease ...
Varonis Systems (VRNS) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results ...
Zacks Investment Research on MSN
AstraZeneca gets accelerated FDA nod for Ultomiris in IgA nephropathy
AstraZeneca AZN announced that the FDA has approved its blockbuster rare disease drug, Ultomiris (ravulizumab), for reducing ...
MedPage Today on MSN
Trio of IgA nephropathy drugs proves mettle in interim analyses
Significant proteinuria reductions reported, but still awaiting eGFR data ...
FILSPARI demonstrated approximately 3x higher complete proteinuria remission rates and 75% lower kidney failure rates versus maximum labeled dose irbesartan in a post hoc analysis of FSGS patients ...
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on October 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of ...
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on October 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants ...
With a late Thursday nod from the FDA to reduce protein levels in the urine of patients with primary immunoglobulin A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results